Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Allogene Therapeutics, Inc. (ALLO) had Return on Investments of -13.13% for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-41.40M |
|
-- |
|
-- |
|
$44.90M |
|
$-44.90M |
|
$3.50M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-41.40M |
|
$-44.90M |
|
$-42.73M |
|
222.04M |
|
222.04M |
|
$-0.19 |
|
$-0.19 |
|
| Balance Sheet Financials | |
$260.72M |
|
$75.90M |
|
$179.05M |
|
$439.77M |
|
$31.83M |
|
-- |
|
$92.61M |
|
$124.44M |
|
$315.33M |
|
$315.33M |
|
$315.33M |
|
223.16M |
|
| Cash Flow Statement Financials | |
$-121.65M |
|
$61.95M |
|
$22.30M |
|
$85.51M |
|
$48.11M |
|
$-37.40M |
|
$29.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.19 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-122.03M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.13% |
|
-13.13% |
|
-9.41% |
|
|
Return on Investments |
-13.13% |
$1.41 |
|
$-0.55 |
|
$-0.55 |
|